Ethical and Public Health Implications of Targeted Screening for Congenital Cytomegalovirus.
Journal
Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
accepted:
13
04
2020
pubmed:
28
6
2020
medline:
26
8
2020
entrez:
28
6
2020
Statut:
ppublish
Résumé
Congenital cytomegalovirus (cCMV) is the most common congenital infection and is associated with sensorineural hearing loss, developmental delays, and visual impairment. The clinical presentation of cCMV is variable, and the majority (80%-90%) of newborns will never manifest any clinical symptoms. Given the clinical heterogeneity of cCMV infection, it is challenging to identify which newborns may benefit from testing. Recently, certain states have implemented a targeted screening program in which newborns who fail the newborn hearing screen are tested for cCMV. Clinicians and legislative bodies have been propelled into debates about the ethical and moral permissibility of a targeted cCMV screening approach. Those who oppose this screening approach describe undue burden on patients, families, and the health care system because the majority of newborns who fail the newborn hearing screen and have cCMV will not go on to have any sequelae related to cCMV, including hearing loss. However, those who support this screening approach cite the importance of early detection and ongoing surveillance for hearing loss and developmental delays in this high-risk group of newborns. This debate will be considered by experts in the field.
Identifiants
pubmed: 32591436
pii: peds.2020-0617
doi: 10.1542/peds.2020-0617
pmc: PMC8171256
mid: NIHMS1707002
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR001862
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
Copyright © 2020 by the American Academy of Pediatrics.
Déclaration de conflit d'intérêts
POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.
Références
Int J Pediatr Otorhinolaryngol. 2015 Dec;79(12):2090-3
pubmed: 26432541
Pediatrics. 2017 Feb;139(2):
pubmed: 28119425
N Engl J Med. 2015 Mar 5;372(10):933-43
pubmed: 25738669
Paediatr Drugs. 2009;11(5):309-21
pubmed: 19725597
J Pediatr. 1997 Apr;130(4):624-30
pubmed: 9108862
Pediatrics. 2015 Apr;135(4):686-93
pubmed: 25733749
J Clin Virol. 2006 Feb;35(2):226-31
pubmed: 16386462
J Infect Dis. 2019 Oct 22;220(11):1790-1796
pubmed: 31310307
Pediatrics. 1964 Jul;34:58-66
pubmed: 14181986
N Engl J Med. 2011 Jun 2;364(22):2111-8
pubmed: 21631323
Pediatr Emerg Care. 2011 Nov;27(11):1009-13
pubmed: 22068058
Rev Med Virol. 2007 Jul-Aug;17(4):253-76
pubmed: 17579921
Hum Exp Toxicol. 1997 Sep;16(9):505-11
pubmed: 9306137
JAMA Pediatr. 2016 Dec 1;170(12):1173-1180
pubmed: 27723885
Pediatrics. 2014 Nov;134(5):972-82
pubmed: 25349318
J Pediatr Pharmacol Ther. 2014 Apr;19(2):72-82
pubmed: 25024666
Pediatrics. 2017 Feb;139(2):
pubmed: 28049114
Pediatrics. 2000 Jul;106(1):E7
pubmed: 10878176